Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants [Phase 1]

View source ↗

Summary

Biogen conducted a Phase 1 study to evaluate safety, tolerability, and pharmacokinetics of single and multiple doses of BIIB033 (opicinumab) in healthy Japanese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BIIB033

Snippet

Sponsor: Biogen | Conditions: Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis | Phase 1 | Status: COMPLETED